Healthcare / Medical DevicesNYSE
$26.52
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 24%
FCF escenarios
weak_data · normalized FCF $12.8M · quality 36.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
16/100
F
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.5B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-79.5%
↓Gross Margin
59.8%
↑Debt/Equity
0.85
↑Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2009–2025 · 16 años de histórico normalizado
Revenue CAGR
+9.5%
FCF CAGR
-2.0%
FCF margin
0.9%
FCF / Net income
-0.02x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $2.25B · net income $-1.18B · FCF $19.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||||||||
| Revenue | $2.25B | $2.25B | $2.11B | $1.71B | $1.56B | $1.43B | $1.12B | $3.33B | $2.19B | $1.94B | $3.19B | $3.43B | $4.62B | $4.21B | $3.91B | $693.4M | $542.0M | $525.0M |
| Net Income | $-1.18B | $-1.18B | $-825.5M | $-33.3M | $-13.3M | $71.7M | $42.6M | $-527.6M | $140.2M | $151.1M | $128.1M | $167.7M | $392.1M | $178.6M | $-64.4M | $4.6M | $16.2M | $23.8M |
| EBITDA | $219.9M | $219.9M | $152.1M | $151.4M | $131.8M | $124.2M | $101.7M | $419.2M | $232.7M | $208.3M | $365.6M | $402.7M | $584.3M | $525.6M | $323.4M | $48.5M | $51.2M | — |
| EPS | -20.75 | -20.75 | -14.93 | -0.61 | -0.25 | 1.40 | 0.93 | -3.89 | 1.16 | 1.22 | 1.04 | 1.34 | 3.02 | 1.54 | -0.92 | 0.10 | 0.37 | — |
| Gross Margin | 59.8% | 59.8% | 56.0% | 58.0% | 55.6% | 54.5% | 53.9% | 42.1% | 33.3% | 34.7% | 31.2% | 31.2% | 32.0% | 31.0% | 29.4% | 34.6% | 35.3% | 35.4% |
| Operating Margin | -50.0% | -50.0% | -36.8% | -3.8% | -4.6% | -4.4% | -5.9% | 6.1% | 6.9% | 7.0% | 7.4% | 7.7% | 8.9% | 9.7% | 3.6% | 3.7% | 6.3% | 7.5% |
| Net Margin | -52.7% | -52.7% | -39.2% | -1.9% | -0.9% | 5.0% | 3.8% | -15.9% | 6.4% | 7.8% | 4.0% | 4.9% | 8.5% | 4.2% | -1.6% | 0.7% | 3.0% | 4.5% |
| Balance Sheet | ||||||||||||||||||
| Debt/Equity | 0.85 | 0.85 | 0.51 | 0.14 | 0.01 | 0.45 | 0.62 | 0.66 | 0.36 | 0.30 | 0.44 | 0.46 | 0.49 | 0.58 | 0.89 | 0.54 | 0.34 | — |
| Cash Flow | ||||||||||||||||||
| Free Cash Flow | $19.9M | $19.9M | $-67.2M | $12.8M | $-161.3M | $251.9M | $187.2M | $5.5M | $156.7M | $150.0M | $183.7M | $233.9M | $301.3M | $290.7M | $90.4M | $42.4M | $49.4M | $27.7M |
| Returns | ||||||||||||||||||
| ROE | -79.5% | -79.5% | -32.2% | -1.0% | -0.4% | 1.6% | 1.2% | -15.3% | 4.3% | 4.3% | 4.4% | 5.5% | 12.5% | 7.1% | -3.4% | 2.4% | 7.5% | 11.0% |
| Growth & Yield | ||||||||||||||||||
| Revenue Growth | 6.7% | 6.7% | 23.5% | 9.2% | 9.6% | 27.3% | -66.3% | 51.7% | 13.2% | -39.2% | -7.2% | -25.7% | 9.9% | 7.5% | 464.5% | 27.9% | 3.2% | — |
| EPS Growth | -39.0% | -39.0% | -2347.5% | -144.0% | -117.9% | 50.5% | 123.9% | -435.3% | -4.9% | 17.3% | -22.4% | -55.6% | 96.1% | 267.4% | -1020.0% | -73.0% | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Unavailable: positive start/end prices are required.